The Federal Government has received blowback following its attempt to slash the Research and Development (R&D) Tax Incentive, which offers a tax incentive to companies which primarily undertake their R&D in Australia.
The proposed changes from the Government would reduce the benefit of the scheme, cutting $1.8bn from the budget over four years, while introducing an estimated further $26m in compliance costs to business under the new Bill.
The Government’s argument is that the R&D Tax Incentive is being claimed by companies for R&D activities that they would undertake regardless, and thus not achieving the Bill’s stated goal- to increase investment and innovation in Australia.
Innovation Intelligence spoke with David Gelb, Global Head R&D Tax Incentives at KPMG, on what the changes mean, and how they will affect Australia’s competitiveness on the world stage.
In his view, “The changes are negative, and are likely to significantly reduce the impact of the R&D Tax Incentive, and accelerate Australia’s downward trend in R&D spending.
“Many large companies will have their R&D incentives halved, and this will have a flow-on effect to SMEs and start-ups which are often reliant on collaborative projects.”
Gelb says that SME’s in critical industries, such as agriculture and manufacturing will be disincentivised from continuing to do R&D given the surprisingly low 4.5% rate on offer.
“The rhetorical carrot of a higher rate is based on the flawed ‘intensity’ model which is unobtainable for many of those businesses.”
AusBiotech, which represents the emerging Australian biotechnology industry, has said, “The vast majority of SMEs and companies in life sciences will be disadvantaged in their claims if the proposed changes go ahead.
“As the most critical policy for the industry, the proposed changes have the potential to significantly damage the sector, and ultimately impact its capacity to deliver new, innovative treatments to Australian patients.”
Business expenditure on R&D has
fallen in Australia
since its peak in the 2013/14 financial year, from $18.8bn to $17.4bn in the 2017/18 figures.
As a proportion of GDP, overall expenditure on R&D in Australia has fallen to an all-time low of 1.79% in 2017/18, well below the OECD average of 2.38% and Business expenditure on R&D as a percentage of GDP has fallen even further to 0.9% in 2017/2018.
Professional Scientists Australia has called for R&D investment to be increased 2.5% of GDP by 2025, reversing the decline of government R&D funding.
A spokesperson from the organisation notes, “This would allow us to sit in the middle of the OECD table, and we should use science and R&D to kick-start growth.
“Investment in science and R&D determines the size and impact of future dividends paid back into the economy. Cuts to science are false economy - we need a coordinated set of policies that encourages and incentivises business investment in R&D so we can support emergent industries and the creation of new jobs.
“Properly funded science and R&D should be central to the federal Government’s commitment to economic growth and increasing our competitiveness in the global economy.”
The United Nations’ World Intellectual Property Organisation (WIPO) annually ranks member states’ innovation potential, with Australia currently ranked 22nd worldwide, and sixth in the region.
This is a fall from Australia’s peak in 2014, when it reached as high as of 17th.
Gelb says that the proposed changes may result in a loss of opportunity for Australia’s economy.
“R&D Incentives exist in many countries, and the measures put forward will place Australia at a significant competitive disadvantage to other countries.
“One of the key strategic reasons to have a R&D incentive is to encourage companies to come and stay. When it comes to the world of tech, it is not difficult to pull up good teams and move to more attractive locations in Singapore or New Zealand,” he explains.
Another significant concern raised by Gelb is that the Government is proposing to retrospectively apply these measures. If enacted as currently draft, this will claw back benefits arising from expenditure companies have already made in relation to:
- Spent funds on R&D
- Employed people to do R&D
- Invested in facilities and equipment to do R&D
- Moved to Australia to do R&D
- Entered into contracts to do R&D
To mitigate some of the negative effects, Gelb says, “There should be grandfathering of any changes for at least two years, on the basis that companies have already made commitments.
“It is unfair for companies who have invested in good faith, on the basis of expecting stability in the law.”